Human papillomavirus disease and vaccines

American Journal of Health-System Pharmacy

Volumn 65, Issue 22, 2008, Pages 2105-2112

  Hutchinson, David J ^a   Klein, Kristin C ^b,c  

^a St Fisher College   (United States)

^b Department of Pharmacy Practice

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Epidemiology; Immunization; Papillomavirus infections; Papillomavirus vaccines; Protocols; Toxicity; Vaccines

Indexed keywords

WART VIRUS VACCINE;

CONDYLOMA ACUMINATUM; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNIZATION; INFECTION PREVENTION; INJECTION SITE REACTION; INJECTION SITE SWELLING; NAUSEA; PRIORITY JOURNAL; REVIEW; UNITED STATES; UTERINE CERVIX CANCER; WART VIRUS;

EID: 56749154780     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070627     Document Type: Review

References (52)

1. Fleurence RL, Dixon JM, Milanova TF et al. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. Am J Obstet Gynecol. 2007; 196:206-12.
2. Insinga RP, Dasbach EJ, Elbasha EH et al. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev. 2007; 16:709-15.
3. Markowitz LE, Dunne EF, Saraiya M et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2):1-24.
4. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997; 102:3-8.
5. Trottier H, Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care. 2006; 12(17, suppl):S462-72.
6. Reisinger KS, Block SL, Lazcano-Ponce E et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007; 26:201-9.
7. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005; 32(suppl 1):S16-24.
8. Franco EL, Villa LL, Sobrinho JP et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999; 180:1415-23.
9. Ho GY, Bierman R, Beardsley L et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998; 338:423-8.
10. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006; 24(suppl 1):S1-15.
11. Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348:518-27.
12. Bosch FX, Lorincz A, Munoz N et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55:244-65.
13. Wallin KL, Wiklund F, Angstrom T et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999; 341:1633-8.
14. Nobbenhuis MA, Walboomers JM, Heimerhorst TJ et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999; 354:20-5.
15. Brown DR, Schroeder JM, Bryan JT et al. Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol. 1999; 37:3316-22.
16. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189:12-9.
17. Saslow D, Castle PE, Cox JT et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. CA Cancer J Clin. 2007; 57:7-28.
18. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57:43-66.
19. Madeleine MM, Daling JR, Carter JJ et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst. 1997; 89:1516-23.
20. Daling JR, Madeleine MM, Schwartz SM et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002; 84:263-70.
21. Carter JJ, Madeleine MM, Shera K et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. 2001; 61:1934-40.
22. Ault KA, for the Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007; 369:1861-8.
23. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European guidelines for quality assurance in cervical cancer screening. J Clin Virol. 2007; 38:189-97.
24. Dunne EF, Markowitz LE. Genital human papillomavirus infection. Clin Infect Dis. 2006; 43:624-9.
25. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995; 87:796-802.
26. Wiley DJ, Douglas J, Beutner K et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis. 2002; 35(suppl 2):S210-24.
27. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, 18] vaccine, recombinant) prescribing information. Whitehouse Station, NJ: Merck & Co.; 2007 Dec.
28. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364:1757-65.
29. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367:1247-55.
30. Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369:2161-70.
31. Villa LL. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine. 2006; 24(suppl 1):S23-8.
32. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6:271-8.
33. Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95:1459-66.
34. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356:1928-43.
35. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356:1915-27.
36. Dawar M, Deeks S, Dobson S. Human papillomavirus vaccines launch a new era in cervical cancer prevention. CMAJ. 2007; 177:456-61.
37. Cervarix (human papillomavirus vaccine types 16 and 18) prescribing information. Rixensart, Belgium: GlaxoSmithKline; 2007 May.
38. Centers for Disease Control and Prevention. CDC vaccine price list. www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm (accessed 2008 Feb 18).
39. Centers for Disease Control and Prevention. VFC: for parents. www.cdc.gov/vaccines/programs/vfc/parents/default.htm#eligible (accessed 2008 Feb 18).
40. Charo RA. Politics, parents, and prophylaxis - mandating HPV vaccination in the United States. N Engl J Med. 2007; 356:1905-8.
41. Eaton DK, Kann L, Kinchen S et al. Youth risk behavior surveillance - United States, 2005. J Sch Health. 2006; 76:353-72.
42. Winer RL, Lee SK, Hughes JP et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157:218-26.
43. Woodman CB, Collins S, Winter H et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001; 357:1831-6.
44. Monk BJ, Wiley DJ. Will widespread human papillomavirus prophylactic vaccination change sexual practices of adolescent and young adult women in America? Obstet Gynecol. 2006; 108:420-4.
45. Weaver BA, Feng Q, Holmes KK et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis. 2004; 189:677-85.
46. GlaxoSmithKline. www.gsk.com/media/pressreleases/2007/2007_05_21_GSK1037. htm (accessed 2008 Sep 24).
47. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008; 359:821-3.
48. Ohri LK. HPV vaccine: immersed in controversy. Ann Pharmacother. 2007; 41:1899-902.
49. Centers for Disease Control and Prevention. HPV: Gardasil and GBS. www.cdc.gov/vaccines/vpd-vac/hpv/downloads/hpv-gardasil-gbs.pdf (accessed 2008 Feb 18).
50. Centers for Disease Control and Prevention. HPV vaccine - questions and answers for the public. www.cdc.gov/vaccines/vpd-vac/hpv/hpv-vacsafe-effic.htm (accessed 2008 Feb 18).
51. Baden LR, Curfman GD, Morrissey S et al. Human papillomavirus vaccine-opportunity and challenge. N Engl J Med. 2007; 356:1990-1.
52. Sawaya GF, Smith-McCune K. HPV vaccination - more answers, more questions. N Engl J Med. 2007; 356:1991-3.